1055 related articles for article (PubMed ID: 25015215)
1. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
[TBL] [Abstract][Full Text] [Related]
2. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
3. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
Jackson TL; Chakravarthy U; Kaiser PK; Slakter JS; Jan E; Bandello F; O'Shaughnessy D; Gertner ME; Danielson L; Moshfeghi DM;
Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
8. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
9. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
[TBL] [Abstract][Full Text] [Related]
11. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
[TBL] [Abstract][Full Text] [Related]
12. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
Regillo CD; Busbee BG; Ho AC; Ding B; Haskova Z
Am J Ophthalmol; 2015 Nov; 160(5):1014-1023.e2. PubMed ID: 26231305
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
[TBL] [Abstract][Full Text] [Related]
14. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
Bloch SB; la Cour M; Sander B; Hansen LK; Fuchs J; Lund-Andersen H; Larsen M
Acta Ophthalmol; 2013 Feb; 91(1):42-7. PubMed ID: 22008284
[TBL] [Abstract][Full Text] [Related]
15. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing.
Heier JS; Boyer D; Nguyen QD; Marcus D; Roth DB; Yancopoulos G; Stahl N; Ingerman A; Vitti R; Berliner AJ; Yang K; Brown DM;
Ophthalmology; 2011 Jun; 118(6):1098-106. PubMed ID: 21640258
[TBL] [Abstract][Full Text] [Related]
16. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS
Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500
[TBL] [Abstract][Full Text] [Related]
18. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
[TBL] [Abstract][Full Text] [Related]
19. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration.
Lala C; Framme C; Wolf-Schnurrbusch UE; Wolf S
Acta Ophthalmol; 2013 Sep; 91(6):526-30. PubMed ID: 22697404
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
Li X; Xu G; Wang Y; Xu X; Liu X; Tang S; Zhang F; Zhang J; Tang L; Wu Q; Luo D; Ke X;
Ophthalmology; 2014 Sep; 121(9):1740-7. PubMed ID: 24793528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]